Re-irradiation and bevacizumab in recurrent high-grade glioma: an effective treatment option

摘要: Re-irradiation has been shown to be a meaningful option for recurrent high-grade glioma (HGG) patients. Furthermore, bevacizumab exerts certain activity in combination with chemotherapy/as monotherapy and was safely tested radiotherapy several previous studies. To our knowledge, this is the largest cohort of patients treated both re-irradiation date. After receiving standard (with or without TMZ) HGG were (10 mg/kg intravenously at d1 d15) during re-irradiation. Median prescribed radiation dose re-treatment 36 Gy, conventionally fractionated. Datasets 71 re-irradiated retrospectively analyzed. Patients either received (N = 57) not 14; other substances 4) sole 10)). In bevacizumab, post-recurrence survival (PRS) (median 8.6 vs. 5.7 months; p 0.003, log-rank test) progression-free (PR-PFS, 5.6 2.5 0.005, test; PFS-6 42.1 % group) significantly increased which confirmed by multivariate analysis. KPS, re-surgery, MGMT methylation status, sex, WHO grade, tumor volume age no significant predictors neither PR-PFS nor PRS (univariate analysis). remains feasible highly effective treatment schedule. Studies on further salvage strategies timing sequential options versus observation are warranted.